Cgm Dexcom denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Dexcom CGM — "Not FDA-Approved"

A continuous glucose monitor (CGM) such as a Dexcom device carries FDA clearance or approval for specific indications. When UnitedHealthcare issues a "not FDA-approved" denial, it almost always means one of two things: (1) the specific indication documented in your chart does not match the labeling the insurer recognizes, or (2) an internal coding or administrative mismatch caused the claim to be routed to a review pathway that did not capture the device's cleared indication. This is a highly appealable denial because the FDA clearance record is a matter of public fact.

## Why This Denial Is Appealable

Dexcom CGM devices hold FDA clearance for diabetes management. If your prescriber ordered the device for a covered indication consistent with that clearance, the denial is contradicted by the public record. Insurers must apply coverage criteria that align with the device's actual regulatory status — not an outdated or incorrect characterization of it.

## Federal Appeal Framework

• Internal appeal (Level 1): You have the right under ACA §2719 and, for employer plans, ERISA §503, to a full-and-fair internal review. Submit within the timeframe shown on your denial letter (commonly 180 days).
• External review: If the internal appeal is denied, you may request independent external review. The external-review window is generally available for up to approximately four months after a final internal denial. An independent review organization (IRO) will evaluate whether the denial was consistent with the device's actual FDA status.
• Expedited review: If you are currently experiencing a medical emergency or if the standard timeline would seriously jeopardize your health, request expedited review, which can be completed within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — chart notes establishing your diabetes diagnosis and clinical need for continuous glucose monitoring. 2. Prescriber letter — a signed medical-necessity letter from your endocrinologist or treating physician citing the FDA-cleared indication and explaining why CGM is medically necessary for your management. 3. FDA clearance reference — publicly available FDA 510(k) clearance or PMA documentation for the specific Dexcom model prescribed (downloadable from the FDA device database). 4. UHC coverage policy — obtain UnitedHealthcare's published coverage determination for CGM devices; confirm the exact indication language and verify your documented diagnosis matches it. 5. Prior treatment history — records of prior glucose monitoring methods, glucose logs, and any hypoglycemic events or glycemic instability that support the clinical rationale.

## Criteria-Mapping Structure

For each requirement listed in UHC's published CGM coverage policy, write a one-sentence response citing the specific page and date of the supporting chart record. Example structure:

| Policy Requirement | Supporting Chart Evidence | |---|---| | Diagnosed with diabetes (type as specified in policy) | [Diagnosis note, date, provider] | | Ordered by a qualified prescriber | [Prescribing physician name, specialty, order date] | | Indication consistent with FDA clearance | [FDA clearance number, device model, indication language] |

Submit this table with your appeal letter so the reviewer can confirm coverage criteria are met without having to search your records.